Dedifferentiation in bone and soft tissue sarcomas: How do we define it? What is prognostically relevant?

IF 2.7 2区 医学 Q2 PATHOLOGY Human pathology Pub Date : 2024-05-01 DOI:10.1016/j.humpath.2024.02.001
Sarah M. Dry
{"title":"Dedifferentiation in bone and soft tissue sarcomas: How do we define it? What is prognostically relevant?","authors":"Sarah M. Dry","doi":"10.1016/j.humpath.2024.02.001","DOIUrl":null,"url":null,"abstract":"<div><p><span><span>Dedifferentiation traditionally is defined by descriptive criteria as a tumor showing an abrupt change in histology from a conventional, classic, low-grade appearing neoplasm to a tumor that is more cellular, pleomorphic and “high grade”, with grading typically being performed by subjective criteria. The dedifferentiated areas range from areas with recognizable histologic differentiation which differs from the primary tumor (such as an </span>osteosarcoma<span><span> arising from a low-grade chondrosarcoma) to areas containing sarcomas without specific histologic differentiation (such as pleomorphic or spindle cell sarcoma). Many, but not all, dedifferentiated tumors are aggressive and associated with significantly shorter survival than their conventional counterparts, even grade 3 conventional tumors. As a result, dedifferentiated tumors are generally considered to be clinically aggressive and as a result, more aggressive surgery or the addition of (neo)adjuvant chemotherapy is often considered. However, long-term (greater than 20 year) survivors are reported in the most common dedifferentiated bone and </span>soft tissue sarcomas. Moreover, use of mitotic criterion for defining dedifferentiation in </span></span>dedifferentiated liposarcoma<span><span><span> as well as grading (by the French system) have been found to be associated with survival. This paper reviews the literature on dedifferentiated chondrosarcoma, dedifferentiated liposarcoma, dedifferentiated </span>chordoma and dedifferentiated parosteal osteosarcoma. As a result of that review, recommendations are advocated to identify evidence-based, objective diagnostic and grading criteria for dedifferentiation that are appropriate for each tumor type. Adding such criteria will improve consistency in diagnosis worldwide, allow easier comparison of </span>clinical research performed on dedifferentiated tumors and help communicate (to patients and clinicians) the tumors with highest risk of clinically aggressive behavior, to allow appropriate and personalized treatment planning.</span></p></div>","PeriodicalId":13062,"journal":{"name":"Human pathology","volume":"147 ","pages":"Pages 139-147"},"PeriodicalIF":2.7000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human pathology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0046817724000157","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Dedifferentiation traditionally is defined by descriptive criteria as a tumor showing an abrupt change in histology from a conventional, classic, low-grade appearing neoplasm to a tumor that is more cellular, pleomorphic and “high grade”, with grading typically being performed by subjective criteria. The dedifferentiated areas range from areas with recognizable histologic differentiation which differs from the primary tumor (such as an osteosarcoma arising from a low-grade chondrosarcoma) to areas containing sarcomas without specific histologic differentiation (such as pleomorphic or spindle cell sarcoma). Many, but not all, dedifferentiated tumors are aggressive and associated with significantly shorter survival than their conventional counterparts, even grade 3 conventional tumors. As a result, dedifferentiated tumors are generally considered to be clinically aggressive and as a result, more aggressive surgery or the addition of (neo)adjuvant chemotherapy is often considered. However, long-term (greater than 20 year) survivors are reported in the most common dedifferentiated bone and soft tissue sarcomas. Moreover, use of mitotic criterion for defining dedifferentiation in dedifferentiated liposarcoma as well as grading (by the French system) have been found to be associated with survival. This paper reviews the literature on dedifferentiated chondrosarcoma, dedifferentiated liposarcoma, dedifferentiated chordoma and dedifferentiated parosteal osteosarcoma. As a result of that review, recommendations are advocated to identify evidence-based, objective diagnostic and grading criteria for dedifferentiation that are appropriate for each tumor type. Adding such criteria will improve consistency in diagnosis worldwide, allow easier comparison of clinical research performed on dedifferentiated tumors and help communicate (to patients and clinicians) the tumors with highest risk of clinically aggressive behavior, to allow appropriate and personalized treatment planning.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
骨与软组织肉瘤中的去分化:如何定义?什么与预后相关?
传统的描述性标准将 "去分化 "定义为肿瘤在组织学上从传统的、典型的、低分化的肿瘤突然转变为更多细胞、多形性和 "高分化 "的肿瘤。发生分化的部位包括组织学分化明显不同于原发肿瘤的部位(如由低分化软骨肉瘤转化而来的骨肉瘤),以及含有肉瘤但组织学分化不明显的部位(如多形性肉瘤或纺锤形细胞肉瘤)。许多但并非所有的去分化肿瘤都具有侵袭性,其生存期明显短于传统肿瘤,即使是 3 级传统肿瘤也是如此。因此,一般认为晚分化肿瘤具有临床侵袭性,因此通常会考虑进行更积极的手术或增加(新)辅助化疗。不过,据报道,最常见的骨和软组织未分化肉瘤都有长期(超过 20 年)存活者。此外,使用有丝分裂标准来定义脂肪肉瘤的去分化以及分级(根据法国系统)也被发现与存活率有关。本文回顾了有关低分化软骨肉瘤、低分化脂肪肉瘤、低分化脊索瘤和低分化骨旁骨肉瘤的文献。根据审查结果,建议确定以证据为基础的、客观的诊断和分级标准,以适用于每种肿瘤类型。增加此类标准将提高全球诊断的一致性,便于比较对再分化肿瘤进行的临床研究,并有助于(向患者和临床医生)传达临床侵袭性行为风险最高的肿瘤,从而制定适当的个性化治疗计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Human pathology
Human pathology 医学-病理学
CiteScore
5.30
自引率
6.10%
发文量
206
审稿时长
21 days
期刊介绍: Human Pathology is designed to bring information of clinicopathologic significance to human disease to the laboratory and clinical physician. It presents information drawn from morphologic and clinical laboratory studies with direct relevance to the understanding of human diseases. Papers published concern morphologic and clinicopathologic observations, reviews of diseases, analyses of problems in pathology, significant collections of case material and advances in concepts or techniques of value in the analysis and diagnosis of disease. Theoretical and experimental pathology and molecular biology pertinent to human disease are included. This critical journal is well illustrated with exceptional reproductions of photomicrographs and microscopic anatomy.
期刊最新文献
Clinicopathologic findings in a cohort of metastases to the stomach Angioimmunoblastic T-cell Lymphoma: Current Diagnostic Insights and Advances. Cyclin D1-negative Mantle Cell Lymphoma. Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: Diagnostic overlaps and defining features. Genetic validation of a TSC2 immunohistochemistry assay in TSC/mTOR-pathway altered renal tumors
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1